发布求助
文献互助 智能选刊 最新文献

Future oncology最新文献

筛选
英文 中文
Accuracy and usability of artificial intelligence chatbot generated chemotherapy protocols. 人工智能聊天机器人生成化疗方案的准确性和可用性。
IF 3.3 4区 医学
Future oncology Pub Date : 2024-04-22 DOI: 10.2217/fon-2023-0950
Efe Cem Erdat, M. Yalçıner, Y. Urun
{"title":"Accuracy and usability of artificial intelligence chatbot generated chemotherapy protocols.","authors":"Efe Cem Erdat, M. Yalçıner, Y. Urun","doi":"10.2217/fon-2023-0950","DOIUrl":"https://doi.org/10.2217/fon-2023-0950","url":null,"abstract":"Background: Medical practitioners are increasingly using artificial intelligence (AI) chatbots for easier and faster access to information. To our knowledge, the accuracy and availability of AI-generated chemotherapy protocols has not yet been studied. Methods: Nine simulated cancer patient cases were designed and AI chatbots, ChatGPT version 3.5 (OpenAI) and Bing (Microsoft), were used to generate chemotherapy protocols for each case. Results: Generated chemotherapy protocols were compared with the original protocols for nine simulated cancer patients. ChatGPT's overall performance was 5 out of 9 on protocol generation, and Bing's was 4 out of 9; this was statistically nonsignificant (p = 1). Conclusion: AI chatbots show both potential and limitations in generating chemotherapy protocols. The overall performance is low, and they should be used carefully in oncological practice.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140675186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis. 转移性尿路上皮癌的治疗模式和临床疗效：德国回顾性真实世界分析。
IF 3.3 4区 医学
Future oncology Pub Date : 2024-04-22 DOI: 10.2217/fon-2023-1065
G. Niegisch, M. Grimm, Fraence Hardtstock, J. Krieger, A. Starry, U. Osowski, S. Guenther, B. Deiters, U. Maywald, Thomas Wilke, M. Kearney
{"title":"Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis.","authors":"G. Niegisch, M. Grimm, Fraence Hardtstock, J. Krieger, A. Starry, U. Osowski, S. Guenther, B. Deiters, U. Maywald, Thomas Wilke, M. Kearney","doi":"10.2217/fon-2023-1065","DOIUrl":"https://doi.org/10.2217/fon-2023-1065","url":null,"abstract":"Aim: This study assessed real-world treatment in patients with metastatic urothelial carcinoma (mUC) in Germany. Materials & methods: Patients diagnosed with mUC from 2015 to 2019 were identified in two claims databases: AOK PLUS and GWQ. Results: 3226 patients with mUC were analyzed; 1286 (39.9%) received systemic treatment within 12 months of diagnosis (platinum-based chemotherapy: 64.2%). Factors associated with receiving treatment were: younger age, male sex, less comorbidity and recent diagnosis. In AOK PLUS and GWQ populations, unadjusted median overall survival (interquartile range) from diagnosis in treated patients was 13.7 (6.8-32.9) and 13.8 (7.1-41.7) months, and in untreated patients was 3.0 (1.2-10.8) and 3.6 (1.2-18.8) months, respectively. Conclusion: A significant proportion of patients with mUC in Germany receive no systemic treatment.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140676993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The causality between Type 2 diabetes and breast cancer: a bidirectional two-sample Mendelian randomization study. 2 型糖尿病与乳腺癌之间的因果关系：双向双样本孟德尔随机研究。
IF 3.3 4区 医学
Future oncology Pub Date : 2024-04-19 DOI: 10.2217/fon-2023-0708
Lihan Zhang, Shuochuan Liu, Guangxing Yue, Hong Niu, Mengjin Hu, Yuling Zheng, Jingwen Tang
{"title":"The causality between Type 2 diabetes and breast cancer: a bidirectional two-sample Mendelian randomization study.","authors":"Lihan Zhang, Shuochuan Liu, Guangxing Yue, Hong Niu, Mengjin Hu, Yuling Zheng, Jingwen Tang","doi":"10.2217/fon-2023-0708","DOIUrl":"https://doi.org/10.2217/fon-2023-0708","url":null,"abstract":"Objective: Observational studies showed that Type 2 diabetes increased the risk of breast cancer, and vice versa. However, it is uncertain whether the link is causal or just due to confounding factors. Using bidirectional Mendelian randomization analysis, we assessed the bidirectional causal relationship from a genetic level. Methods: Large genome-wide association studies yielded summary-level data for Type 2 diabetes and breast cancer. Results: Genetically predicted Type 2 diabetes presented no statistically significant association with overall breast cancer or its subtypes. Similarly, genetically predicted overall breast cancer or its subtypes had no causal effect on Type 2 diabetes. Sensitivity analyses yielded similar results. Conclusion: Our bidirectional Mendelian randomization studies revealed no causal links between Type 2 diabetes and breast cancer.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140684479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond. 贝珠替凡：治疗冯-希佩尔-林道氏病及其他疾病的新型疗法。
IF 3.3 4区 医学
Future oncology Pub Date : 2024-04-19 DOI: 10.2217/fon-2023-0679
Lauren Curry, Maryam Soleimani
{"title":"Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.","authors":"Lauren Curry, Maryam Soleimani","doi":"10.2217/fon-2023-0679","DOIUrl":"https://doi.org/10.2217/fon-2023-0679","url":null,"abstract":"The identification of the VHL gene and its role in regulating the hypoxia-inducible factor signaling pathway has helped to revolutionize the treatment of renal cell carcinoma (RCC). Belzutifan is a novel small-molecule inhibitor of hypoxia-inducible factor 2α which has demonstrated efficacy in treating von Hippel-Lindau (VHL) disease, earning regulatory approvals for this indication. There is also early evidence for efficacy in sporadic RCC. Belzutifan has a favorable safety profile. Several clinical trials are currently ongoing, which should help in identifying this promising drug's role in RCC and beyond. This review summarizes the history, pharmacology and clinical evidence for belzutifan use to date, and also explores unanswered questions as they relate to this novel therapeutic agent.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140684301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Race/ethnicity and socioeconomic position in emergency department utilization in patients with hepatocellular carcinoma. 肝细胞癌患者使用急诊科的种族/民族和社会经济地位。
IF 3.3 4区 医学
Future oncology Pub Date : 2024-04-19 DOI: 10.2217/fon-2023-0412
Daniel Lin, Ruoding Tan, Christie Teigland, Sairy Hernandez, Seung Kim, Karl M Kilgore
{"title":"Race/ethnicity and socioeconomic position in emergency department utilization in patients with hepatocellular carcinoma.","authors":"Daniel Lin, Ruoding Tan, Christie Teigland, Sairy Hernandez, Seung Kim, Karl M Kilgore","doi":"10.2217/fon-2023-0412","DOIUrl":"https://doi.org/10.2217/fon-2023-0412","url":null,"abstract":"Aim: Evaluate the association of race/ethnicity and socioeconomic position (SEP) on emergency department (ED) visits for patients with hepatocellular carcinoma (HCC), which may reflect access to and quality of cancer care. Materials & methods: Patients with HCC identified from a commercial multi-payer claims database between 2015 and 2018 were matched to near-neighborhood social determinants of health (SDOH) and stratified by race/ethnicity and SEP (proxied by annual household income). Analyses evaluated the effect of race/ethnicity and SEP on ED utilization, adjusting for SDOH, demographic and clinical characteristics using multivariable regression methods. Results: A total of 22,247 patients were included. Black and Hispanic patients had 43 and 18% higher ED utilization than White patients at higher-income levels (p < 0.01); these differences were nonsignificant at lower-income. Regardless of income level, Asian patients had lower ED utilization. Conclusion: Further research on the intersectionality between race/ethnicity, SEP and other SDOH may guide structural-level interventions to address health inequities.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140683381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B. 尼拉帕利治疗 BRCA 基因突变胆道癌、胰腺癌和其他胃肠道癌症的 II 期试验：NIR-B.
IF 3.3 4区 医学
Future oncology Pub Date : 2024-04-17 DOI: 10.2217/fon-2023-0348
Y. Kawamoto, C. Morizane, Yoshito Komatsu, S. Kondo, M. Ueno, Satoshi Kobayashi, Masayuki Furukawa, Lingaku Lee, Taroh Satoh, D. Sakai, Masafumi Ikeda, H. Imaoka, Arisa Miura, Yutaka Hatanaka, Isao Yokota, Yoshiaki Nakamura, Takayuki Yoshino
{"title":"Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.","authors":"Y. Kawamoto, C. Morizane, Yoshito Komatsu, S. Kondo, M. Ueno, Satoshi Kobayashi, Masayuki Furukawa, Lingaku Lee, Taroh Satoh, D. Sakai, Masafumi Ikeda, H. Imaoka, Arisa Miura, Yutaka Hatanaka, Isao Yokota, Yoshiaki Nakamura, Takayuki Yoshino","doi":"10.2217/fon-2023-0348","DOIUrl":"https://doi.org/10.2217/fon-2023-0348","url":null,"abstract":"Due to the widespread use of cancer genetic testing in gastrointestinal cancer, the BRCA1/2 genetic mutation has been identified in biliary tract cancer as well as pancreatic cancer. Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor, and PARP inhibitors exert their cytotoxicity against cancer cells in the context of homologous recombination deficiency, such as BRCA mutations, via the mechanism of synthetic lethality. The aim of this phase II NIR-B trial is to evaluate the efficacy and safety of niraparib for patients with unresectable advanced or recurrent biliary tract cancer, pancreatic cancer or other gastrointestinal cancers with germline or somatic BRCA1/2 mutations revealed by genetic testing. The primary end point is an investigator-assessed objective response rate in each cohort. Clinical Trial Registration: jRCT2011200023 (ClinicalTrials.gov).","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140691058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. METexon14 跳越突变非小细胞肺癌标准治疗的有效性：一项真实世界研究。
IF 3.3 4区 医学
Future oncology Pub Date : 2024-04-17 DOI: 10.2217/fon-2023-1064
Muhammad Furqan, Siddharth Karanth, R. Goyal, B. Cai, Julien Rombi, Keith L Davis, N. Caro, T. Saliba
{"title":"Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.","authors":"Muhammad Furqan, Siddharth Karanth, R. Goyal, B. Cai, Julien Rombi, Keith L Davis, N. Caro, T. Saliba","doi":"10.2217/fon-2023-1064","DOIUrl":"https://doi.org/10.2217/fon-2023-1064","url":null,"abstract":"Aim: To assess real-world clinical outcomes with standard therapies for advanced non-small-cell lung cancer (aNSCLC) with METexon14 skipping mutation (METex14). Methods: In an oncologists-led retrospective review of medical records, data were abstracted and analyzed for patients initiating first-line (1L) systemic therapy after 1 January 2017. Results: In total 287 aNSCLC patients with METex14, the real-world best overall response rate was 73.4% for capmatinib (n = 146), 68.8% for immunotherapy (IO) monotherapy (n = 48), 52.0% for chemotherapy (CT, n = 30), and 54.8% for IO + CT (n = 63). As compared with capmatinib, patients receiving IO (hazard ratio [HR]: 1.57; 95% CI: 0.77-3.20; p = 0.220), CT (HR: 2.41; 95% CI: 1.19-4.85; p = 0.014) and IO + CT (HR: 2.33; 95% CI: 1.35-4.04; p = 0.003) had higher rates of progression. Further, patients receiving CT (HR: 4.43; 95% CI: 1.54-12.75; p = 0.006) and IO + CT (HR: 3.53, 95% CI: 1.41-8.85; p = 0.007) had higher rates of mortality than patients receiving capmatinib. Conclusion: The study showed better clinical outcomes with capmatinib than other standard therapies in 1L setting for aNSCLC harboring METex14.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140692014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan. 日本 3L axicabtagene ciloleucel 与 tisagenlecleucel 和 lisocabtagene maraleucel 的成本效益分析。
IF 3.3 4区 医学
Future oncology Pub Date : 2024-04-10 DOI: 10.2217/fon-2023-1114
Saaya Tsutsué, Shinichi Makita, Hiroya Asou, Hiroyuki Matsuda, Reiko Yamaura, Todd D Taylor
{"title":"Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan.","authors":"Saaya Tsutsué, Shinichi Makita, Hiroya Asou, Hiroyuki Matsuda, Reiko Yamaura, Todd D Taylor","doi":"10.2217/fon-2023-1114","DOIUrl":"https://doi.org/10.2217/fon-2023-1114","url":null,"abstract":"Aim: Cost-effectiveness analysis (CEA) was performed to compare axicabtagene ciloleucel (axi-cel) with tisagenlecleucel (tisa-cel) and lisocabtagene (liso-cel) for treatment of relapsed or refractory large B-cell lymphoma in adult patients after ≥2 lines of therapy in Japan. Materials & methods: Cost-effectiveness analysis was conducted using the partition survival mixture cure model based on the ZUMA-1 trial and adjusted to the JULIET and TRANSCEND trials using matching-adjusted indirect comparisons. Results & conclusion: Axi-cel was associated with greater incremental life years (3.13 and 2.85) and incremental quality-adjusted life-years (2.65 and 2.24), thus generated lower incremental direct medical costs (-$976.29 [-¥137,657] and -$242.00 [-¥34,122]), compared with tisa-cel and liso-cel. Axi-cel was cost-effective option compared with tisa-cel and liso-cel from a Japanese payer's perspective.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140720519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer. Pembrolizumab 联合化疗一线治疗晚期三阴性乳腺癌。
IF 3.3 4区 医学
Future oncology Pub Date : 2024-04-10 DOI: 10.2217/fon-2023-0301
A. Haiderali, Min Huang, W. Pan, Katherine G Akers, Dylan Maciel, Andrew M Frederickson
{"title":"Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer.","authors":"A. Haiderali, Min Huang, W. Pan, Katherine G Akers, Dylan Maciel, Andrew M Frederickson","doi":"10.2217/fon-2023-0301","DOIUrl":"https://doi.org/10.2217/fon-2023-0301","url":null,"abstract":"Aim: A systematic review and network meta-analysis (NMA) was performed to evaluate the efficacy of first-line treatments for locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) patients. Materials & methods: Databases were searched for randomized controlled trials evaluating first-line treatments for locally recurrent unresectable or metastatic TNBC patients. NMA was performed to estimate relative treatment effects on overall and progression-free survival between pembrolizumab + chemotherapy and other interventions. Results: NMA including eight trials showed that the relative efficacy of pembrolizumab + chemotherapy was statistically superior to that of other immunotherapy- or chemotherapy-based treatment regimens. Conclusion: Pembrolizumab + chemotherapy confers benefits in survival outcomes versus alternative interventions for the first-line treatment of locally recurrent unresectable or metastatic TNBC patients.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140716274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy combined with cranial radiotherapy for driver-negative non-small-cell lung cancer brain metastases: a retrospective study. 免疫疗法联合头颅放疗治疗驱动因素阴性的非小细胞肺癌脑转移：一项回顾性研究。
IF 3.3 4区 医学
Future oncology Pub Date : 2024-04-09 DOI: 10.2217/fon-2023-1061
Shuangqing Lu, Xiaokang Guo, Zhengqiang Yang, Yulan Sun, Jiling Niu, X. Jing, Hui Zhu
{"title":"Immunotherapy combined with cranial radiotherapy for driver-negative non-small-cell lung cancer brain metastases: a retrospective study.","authors":"Shuangqing Lu, Xiaokang Guo, Zhengqiang Yang, Yulan Sun, Jiling Niu, X. Jing, Hui Zhu","doi":"10.2217/fon-2023-1061","DOIUrl":"https://doi.org/10.2217/fon-2023-1061","url":null,"abstract":"Background: This study assesses immune checkpoint inhibitors' efficacy for non-small-cell lung cancer (NSCLC) with brain metastases (BM) and explores the role of cranial radiation therapy (CRT) in the immunotherapy era. Methods: The retrospective analysis screened NSCLC patients with BMs from July 2018 to December 2021. Treatment involved chemotherapy combined with immune checkpoint inhibitors as the first-line, with patients divided into CRT and non-CRT groups. Overall survival (OS), progression-free survival and intracranial progression-free survival were calculated and compared. Results: Among 113 patients, 74 who received CRT had significantly better median OS (not reached vs 15.31 months), particularly among those with one to three BMs. Factors correlating with better OS included CRT, PD-L1 expression and diagnosis-specific graded prognostic assessment scores. Conclusion: Integrating CRT with anti-PD-1 therapy notably enhanced long-term survival in NSCLC patients with BMs.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140726430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信